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Abstract
Introduction: Obesity-related disturbances are considered to be risk factors for
cardiovascular disease (CVD). Chromium is shown to improve carbohydrate and
lipid metabolism. Conflicting data on effects of chromium supplementation in
humans are published. The aim of the study was to assess the concentrations
of serum chromium during the 75-g oral glucose tolerance test (OGTT) in obese
persons.
Material and methods: Fourty-eight centrally obese Caucasians, apparently healthy,
using neither special diet nor mineral supplementation, were enrolled in the
study. During the OGTT, 0-min and 120-min concentrations of plasma glucose 
(G 0’, G 120’), serum insulin (Ins 0’, Ins 120’) and chromium (Cr 0’, Cr 120’) were
determined. Plasma lipids, apolipoproteins A and B, and serum uric acid were
measured at 0 min only. For parameters assessed during the OGTT, the 
difference D = [(120’ concentration) – (0’ concentration)] was calculated. Contr  -
adictory tendencies of Cr 120’ were observed; thus the difference of serum
chromium concentrations, DCr = [(Cr 120’) – (Cr 0’)], was used to establish the
positive DCr group with DCr > 0 (PosDCr: n = 24; 9 male/15 female) and the
negative DCr group with DCr < 0 (NegDCr: n = 24; 8 male/16 female). 
Results: The studied groups were comparable as far as their metabolic
parameters are concerned, except higher G 120’ (p = 0.043) and DG (p = 0.048),
and lower Cr 120’ (p < 0.000), which were observed in the NegDCr group. The
NegDCr persons showed inverse correlations between Cr 0’ and systolic and
diastolic blood pressure.
Conclusions: We suggest that the studied centrally obese persons differed in
chromium metabolism. In subjects “consuming” Cr during the OGTT, chromium
status may be associated with increased risk for CVD.
Key words: abdominal obesity, trace element, blood pressure, glucose. 
Introduction
Central obesity is considered to be a risk factor for type 2 diabetes and
cardiovascular disease (CVD). The coexistence of obesity, hypertension,
and lipid and glucose abnormalities is under worldwide discussion,
composing definition of the metabolic syndrome [1]. The increasing
prevalence of overweight and obesity in humans all over the world stresses
the importance of obesity-related disturbances [2]. Confirmed activities
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and new insights to prevent the development of
metabolic abnormalities and subsequent CVD in
humans are needed [3, 4]. 
Chromium was discovered to improve carbo  -
hydrate and lipid metabolism, especially in type 2
diabetics. This trace element may regulate insulin
action and facilitate glucose transfer into cells.
Much lower amounts of the hormone are required,
since chromium increases insulin efficiency [5, 6].
The hypothesis of serum chromium statement
sharing insulin action in insulin-sensitive cells is
presented in Figure 1.
Chromium exists in our environment in several
oxidation states, including metallic (Cr0); trivalent
(Cr+3) – a predominant stable biological form; and
hexavalent (Cr+6) – a strong oxidizing agent, highly
toxic [7]. Some controversies have been published
about serum chromium concentrations in healthy
persons, for years. Reported values vary from 
0.9-3.0 nmol/l to 2.4-4.7 nmol/l [8]. About 9.0 nmol/l
serum chromium concentration was observed in
babies, which declined until 5.0-6.0 nmol/l in adults
and elderly, and decreased more in type 2 diabetic
patients to 3.8 nmol/l [9]. Nowadays nutrients might
not provide appropriate doses of trace elements. Post-
industrial environmental changes and new nutritional
habits, such as highly refined and processed food, can
result in chromium deficiency in particular [10]. 
Decreased serum chromium levels are observed
in patients with diabetes [11]. We were interested
in the conflicting data reporting either a lack of
effect [12] or significant improvement [13] on
carbohydrate and lipid metabolism under chromium
supplementation. Furthermore, we realized the
potential influence of this trace element on insulin
sensitivity, which inspired us to plan this research. 
The aim of the study was to assess concen  -
trations of serum chromium during the oral glucose
tolerance test and their relations to blood pressure
and some metabolic factors in centrally obese
persons.
Material and methods
Subjects and settings
The study was performed in accordance with the
Declaration of Helsinki for human research and the
study protocol was approved by the Bioethical
Committee of Poznan University of Medical
Sciences. The subjects participating in the study
gave informed consent to the study procedure.
Non-smoking adult Caucasians, residents of
Poznan city, without any acute disease or chronic
disorder but centrally obese according to the
International Diabetes Federation (IDF) 2005 criteria
regarding waist circumference of at least 94 cm for
males and at least 80 cm for females [1, 2], were
invited to the study. Both females and males using
no special diet or mineral supplementation
underwent the study procedure and were qualified
Figure 1. The hypothesis of chromium metabolism during the oral glucose tolerance test
Cr+3 – trivalent chromium, Pro – plasma protein (most likely transferrin), LMWCr – low molecular weight chromium binding substance,
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for the 75-g oral glucose tolerance test (OGTT)
according to WHO recommendations [14]. 
Finally 48 persons (17 males, 31 females) aged
from 25 to 65 years old, since the difference of
serum chromium concentrations (DCr) had been
calculated during the OGTT, were categorized into
two groups of subjects: the positive DCr group,
PosDCr (n = 24, 9 males, 15 females), and the
negative DCr group, NegDCr (n = 24, 8 males, 
16 females).
Measurements
The complete physical examination, including
the systolic (SBP) and diastolic arterial blood
pressure (DBP), the measurement of waist
circumference (cm), the body fat composition 
(% fat, FAT) by bioimpedance using BodyStat
equipment and the calculation of body mass index
(BMI = kg/m2) were performed. The arterial blood
pressure was assessed twice on the left arm with
an appropriate cuff size, using the sphygmo  -
manometer MEDEL Palm Pro 91431 (Medel, Italy),
after at least 15 min’ rest in a sitting position, and
the result was expressed as the mean value of two
measurements.
The studied persons underwent collection of
ulnar venous blood twice: fasting at 0 min (0’) and
at 120 min (120’) of the 75-g OGTT. During the OGTT
concentrations of plasma glucose (G), serum insulin
(Ins) and chromium (Cr) were determined twice 
(0’ and 120’). Plasma total cholesterol (T-C), HDL
cholesterol (HDL-C), triglycerides (TG), apolipopro  -
tein A (apo A), apolipoprotein B (apo B) and uric acid
(UA) were assessed fasting. LDL cholesterol (LDL-C)
was calculated according to the Friedewald formula, 
LDL-C [mmol/l] = [(T-C) – (HDL-C) – (TAG/2,2)]. 
Plasma glucose, lipids and uric acid concen  -
trations were determined by enzymatic methods,
and apo A and apo B were measured by an
immunoenzymatic method, on a Dimension Xpand
Plus integrated analyser (Siemens Healthcare, USA).
The reference sera level 1 and level 2 (Randox,
United Kingdom) were used for monitoring the
accuracy of the determinations. 
Fasting serum samples designated for insulin
and chromium measurements were frozen and
stored at –25°C until assayed, separately.
Serum insulin was measured by the ELISA
method (BioSource, Belgium) on a microplate reader
(Sunrise Tecan, Switzerland), with a sensitivity of
0.15 mIU/l. The intra-assay coefficient of variation
(CV) and inter-assay CV for insulin measurements
were calculated as 3.5% and 4.3%, respectively.
Insulin resistance indices, i.e. the insulin resistance
ratio, IR = (Ins/G 0’[mg/dl]), and Homeostatic Model
Assessment for Insulin Resistance, HOMA-IR =
(G0'[mmol/l]*Ins/22,5), were calculated. 
Serum chromium concentration was determined
using graphite furnace atomic absorption spectro  -
scopy (Perkin Elmer Zeeman 3030 spectro  meter,
PerkinElmer Instruments, USA) with intra-assay CV
of 4.2%. The reference sera SeronormTM Trace
Elements Serum level 1 and level 2 (Sero AS,
Norway) were used for monitoring the accuracy of
the determinations.
For parameters determined during the OGTT, 
the difference D = {(120’ concentration) – 
(0’ concentration)} was calculated. Contradictory
directions of serum Cr 120’ concentrations were
observed and the difference of serum chromium
concentrations, DCr = ([Cr 120’] – [Cr 0’]), was used
to establish the positive DCr group with DCr > 0
(PosDCr: n = 24, 9 male/15 female) and the negative
DCr group with DCr < 0 (NegDCr: n = 24, 8 male/16
female).
Statistical analysis
Statistical calculations were performed using the
program Statistica 6.0 for Windows. The normality
of value distributions was checked by Shapiro-Wilk
test. Significant differences between studied groups
were calculated by nonparametric Mann-Whitney U
test and correlations were described by Spear  man’s
coefficient (R), while p < 0.05. All results are shown
as mean ± standard deviation and median (in
parentheses).
Results
The characteristics of subjects with respect to
their gender revealed no differences between males
and females, except FAT and waist, which is in
accordance with gender-related body mass
composition and body fat distribution, and Ins 120’
and DIns both higher in the female group. The details
are presented in Table I. The whole study population
exhibited a decreased tendency for serum Cr
concentration as compared with literature reference
values obtained from normal body mass and normal
glucose tolerance persons, but remaining within
ranges for humans in general [8, 9].
Following the aim of the study, persons were
categorized according to a positive (PosDCr) or
negative (NegDCr) difference of serum chromium
concentrations during the OGTT. The clinical and
laboratory data of the studied groups are shown in
Table II. 
In the PosDCr group 58% normal and 42% newly
diagnosed abnormal glucose tolerance (dysgly  -
caemia) subjects were diagnosed, while in the
NegDCr group, 46% and 54% were diagnosed,
respectively. The exact data are presented in Table III. 
The NegDCr persons demonstrated higher G120’,
lower Cr 120’ and DCr compared with PosDCr
persons. 260 Arch Med Sci 2, April / 2011
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Parameters Males Females Significant 
(n = 17) (n = 31) difference
Age [years] 46.2 ±10.6  49.4 ±10.2 
(48.0) (52.0)
BMI [kg/m2] 34.8 ±6.9  36.6 ±6.5 
(34.1) (35.3)
Waist [cm] 118.9 ±17.7  109.9 ±14.9  p = 0.045
(116.0) (107.0)
FAT [%] 35.6 ±5.2  46.3 ±7.7  p = 0.000
(34.6) (46.9)
SBP [mmHg] 138.6 ±11.0  143.9 ±21.4
(140.0) (150.0)
DBP [mmHg] 88.5 ±7.9  92.3 ±11.1 
(90.0) (90.0)
G 0’ [mmol/l] 5.79 ±1.70  5.52 ±0.72 
(5.14) (5.40)
G 120’ [mmol/l] 6.82 ±3.32  7.31 ±2.73 
(6.34) (6.84)
DG [mmol/l] 1.03 ±2.05  1.79 ±2.19 
(1.22) (1.35)
Ins 0’ [mU/l] 54.0 ±56.3  40.9 ±28.3 
(21.9) (29.4)
Ins 120’ [mU/l] 137.5 ±152.6  209.6 ±165.1  p = 0.045
(80.8) (142.7)
DIns [mU/l] 83.5 ±138.0  168.7 ±159.9  p = 0.036
(30.5) (98.2)
IR (Ins 0’/G 0’) 0.550 ±0.635  0.418 ±0.281 
(0.230) (0.297)
HOMA-IR 14.4 ±16.9  10.0 ±7.4 
(5.6) (7.7)
T-C [mmol/l] 5.51 ±0.85  5.47 ±1.11 
(5.43) (5.28)
TAG [mmol/l] 1.99 ±0.97  1.61 ±0.77 
(1.86) (1.50)
HDL-C [mmol/l] 1.41 ±0.99  1.26 ±0.29 
(1.19) (1.22)
LDL-C [mmol/l] 3.38 ±0.71  3.049 ±1.09 
(3.44) (3.19)
Apo A [mg/dl] 117.2 ±42.2  131.6 ±37.2 
(131.6) (132.9)
Apo B [mg/dl] 116.7 ±20.7  113.5 ±21.7 
(117.1) (109.1)
U A [μmol/l] 330.1 ±103.8  314.6 ±80.1 
(346.2) (318.8)
Cr 0’ [nmol/l] 2.76 ±0.29  2.86 ±0.23 
(2.85) (2.92)
Cr 120’ [nmol/l] 2.79 ±0.53  3.03 ±0.85 
(2.71) (2.88)
DCr [nmol/l] 0.037 ±0.66  0.17 ±0.89 
(0.21) (–0.02)
Table I. Characteristics of the study population –
comparison between males and females invest  -
igated. Data are presented as mean ± standard
deviation and median (in parentheses)
Parameters Pos DCr Neg DCr Significant
(n = 24) (n = 24) difference
Age [years] 48.7 ±11.3  47.9 ±9.5 
(52.0) (49.5)
BMI [kg/m2] 35.5 ±5.6  36.4 ±7.7 
(34.6) (35.6)
Waist [cm] 110.4 ±14.7  115.8 ±17.8 
(107.5) (113.0)
FAT [%] 42.0 ±9.4  43.0 ±8.0 
(43.1) (43.3)
SBP [mmHg] 139.5 ±14.8  144.6 ±21.5 
(140.0) (145.0)
DBP [mmHg] 90.5 ±9.4  91.5 ±11.1 
(90.0) (90.0)
G 0’ [mmol/l] 5.48 ±1.26  5.76 ±1.06 
(5.26) (5.43)
G 120’ [mmol/l] 6.48 ±2.91  7.81 ±2.87  p = 0.043
(5.62) (7.09)
DG [mmol/l] 1.00 ±2.03  2.06 ±2.19  p = 0.048
(0.73) (1.80)
Ins 0’ [mU/l] 48.6 ±44.5  42.4 ±36.5 
(24.4) (27.6)
Ins 120’ [mU/l] 164.3 ±150.1  203.9 ±175.8 
(108.9) (138.1)
DIns [mU/l] 115.7 ±147.2  161.5 ±165.3 
(50.1) (92.8)
IR (Ins 0’/G 0’) 0.506 ±0.499  0.423 ±0.373 
(0.281) (0.254)
T-C [mmol/l] 5.35 ±1.08  5.62 ±0.97 
(5.10) (5.60)
TAG [mmol/l] 1.60 ±0.75  1.89 ±0.95 
(1.53) (1.81)
HDL-C [mmol/l] 1.42 ±0.85  1.21 ±0.26 
(1.21) (1.22)
LDL-C [mmol/l] 3.34 ±1.03  3.56 ±0.92 
(3.06) (3.55)
Apo A [mg/dl] 121.4 ±44.6  130.3 ±34.3 
(130.1) (133.3)
Apo B [mg/dl] 111.6 ±19.5  117.6 ±22.6 
(108.3) (115.1)
U A [μmol/l] 314.6 ±95.11  325.8 ±82.9 
(333.1) (333.1)
Cr 0’ [nmol/l] 2.71 ±0.25  2.94 ±0.21  p = 0.0025
(2.67) (2.98)
Cr 120’ [nmol/l] 3.48 ±0.65  2.42 ±0.41  p < 0.000
(3.27) (2.53)
DCr [nmol/l] 0.77 ±0.60  (–0.52) ±0.34  p < 0.000
(0.56) (–0.45)
Table II. Characteristics of the studied groups. Data
are presented as mean ± standard deviation and
median (in parentheses)Arch Med Sci 2, April / 2011 261
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Subjects with a negative difference of chromium
concentrations during the OGTT (NegDCr) presented
inverse correlations for Cr0’ and SBP (Figure 2), and
Cr0’ and DBP (Figure 3).
Discussion
Investigators agree that widespread nutritional
chromium deficiency of the human body is
observed in developed countries. Contemporary
diets may be low in this essential trace element,
because of soil depletion, refined food, excessive
sugar consumption, lack of exercise and obesity [9].
It is interesting that unequivocal Cr deficiency has
been demonstrated only in humans on total
parenteral nutrition with no chromium added.
Paradoxically, morbidly obese patients may also
demonstrate a nutritional deficiency, e.g. concerning
minerals [15, 16]. 
A few studies have assessed serum chromium
concentrations in a context of risk factors for CVD.
Roussel et al. investigated the effects of hormonal
replacement therapy (HRT) on chromium status and
metabolic parameters in French postmenopausal
females. They observed lower serum Cr con  cen  -
tration in untreated women (1.35 ±0.16 nmol/l)
compared with HRT-receiving females (1.93 ±0.16
nmol/l) improving their carbohydrate and lipid
metabolism; otherwise both groups presented
decreased levels as far as our study population is
concerned [17].
Another unique study presented chromium
status and glucose tolerance in Saudi men with and
without CVD. The authors observed higher serum
chromium concentrations as compared with our
studied subjects. This could be explained by either
possible different nutrients intake or lower BMI
(overweight) of that population in contrast to higher
BMI (obese) of our study group. Even then,
a worldwide tendency to meet the lowest serum Cr
in diabetic patients, among studied normal glucose
tolerance and impaired glucose tolerance (IGT) and
diabetic Saudi subjects, was obvious. Alissa et al.
found serum chromium (OR 0.99, 95% CI 0.985-
0.995, p < 0.0001), urinary Cr (OR 0.988, 95% CI
0.981-0.995,  p  < 0.001) and plasma glucose 
(OR 1.127, 95% CI 1.0-1.269, p < 0.05) to be in  -
dependently associated with the presence of
coronary heart disease (CHD) [18].
Despite a lack of studies on serum chromium
status, the influence of the essential trace element
on metabolic risk factors for CVD is of significant
interest to clinicians.
There are numerous studies evaluating the
effects of chromium supplementation on
carbohydrate and lipid metabolism parameters in
humans and in experimental studies. Papers
document the improved glucose tolerance and lipid
metabolism in type 2 diabetics [19]. Naturally
occurring compounds, such as chromium and
polyphenols from cinnamon improve all signs of the
metabolic syndrome in type 2 diabetic patients as
well [20]. These findings conflict with studies
showing no effects on carbohydrate metabolism
and serum lipid concentrations, especially in patients
without type 2 diabetes [21]. There were no changes
in insulin sensitivity, serum lipids and body com  -
NGT Dysglycaemia
IFG IGT T2DM
Pos DCr (n = 24) n = 14 (58%) n = 4 (17%) n = 4 (17%) n = 2 (8%)
Neg DCr (n = 24) n = 11 (46%) n = 3 (12.5%) n = 7 (29%) n = 3 (12.5%)
NGT – normal glucose tolerance, IFG – impaired fasting glycaemia, IGT – impaired glucose tolerance, T2DM – type 2 diabetes mellitus
Table III. Glucose tolerance in the studied groups, according to OGTT results obtained
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Figure 2. The correlation between SBP and Cr0’ in
the NegDCr group, described by Spearman coef  -
ficient, R; p < 0.05
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position after chromium supplementation in healthy
elderly subjects [22]. Chromium supplementation
did not improve key features of the metabolic
syndrome in non-diabetic obese patients, either
[23, 24]. 
Trying to explain the above-mentioned results,
it was proposed that diabetic subjects may have
altered chromium metabolism, as both absorption
and excretion may be higher compared with non-
diabetics [25]. 
Among supplementation studies we have found
one paper concerning an influence of 12-week
chromium supplementation on metabolic charac  -
teristics in moderately obese women under an
exercise program. The authors assessed, among
other things, some biochemical parameters,
including plasma chromium, before (fasting) and 
1 h and 2 h after a standardized 300-kcal 74-g
carbohydrate meal. Volpe et al. did not note any
changes for plasma Cr concentrations in response
to a high-carbohydrate meal, which the present
study does report during the OGTT. The authors
explained this part of their investigation with
neither diabetes nor pre-diabetes diagnosed in
studied females [26].
Frauchiger, Wenk and Colombani focused on
acute chromium supplementation during the test
meal, providing 75 g of available carbohydrates
(imitating the OGTT). The authors observed
a beneficial effect on postprandial glucose level in
most (called responders) but not all subjects. The
two ways of serum chromium utilization we have
discovered might explain the results of that study;
our investigated NegDCr group could reflect their
“non-responders” [27].
There are no data reflecting serum chromium
status during the OGTT among published studies
yet. Our preliminary results suggest that the studied
centrally obese persons may differ in chromium
metabolism, increasing or decreasing the difference
of serum chromium concentrations (DCr) during the
OGTT. In persons “consuming” chromium during
the OGTT (NegDCr group) decreased fasting Cr is
related to elevated both systolic and diastolic blood
pressure. These subjects presented higher
postprandial glucose (G 120’) levels. The tendencies
to increase T-C, TAG and LDL-C, and decrease HDL-C,
were observed in the group as well. These findings
are in agreement with the scarce data concerning
relationships between decreased serum Cr and
increased risk for CHD [18].
Limitations of our study might include the lack
of a control group with normal waist and body mass
index subjects. It could be interesting if a dispersion
of serum chromium concentration during the OGTT
is a feature of centrally obese subjects or could
characterize humans in general.
Summing up, apart from anthropometric
characteristics of obesity, metabolic parameters of
the studied subjects could be more or less
associated with serum chromium status. Our
studied NegDCr persons seem to be more advanced
in metabolic disturbances compared with the
PosDCr group. 
Regarding features of the metabolic syndrome,
the way of chromium utilization may affect blood
pressure and glucose metabolism especially. This
finding might be applied to clinical practice if it is
confirmed in further investigations.
In conclusion, our data, documenting contr  -
adictory changes of serum chromium concen  -
trations during the OGTT, could explain the different
metabolic results for chromium supplementation
found in the cited literature. Persons who utilize
chromium intensively during the OGTT might
require more trivalent chromium for the possible
benefit from this factor. 
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